Targeting MAPK (Ras/ERK) and PI3K/Akt pathways in pituitary tumorigenesis

Basit Öğe Kaydı
dc.contributor.authorCakir, Mehtap
dc.contributor.authorGrossman, Ashley B.
dc.date.accessioned2020-03-26T17:40:25Z
dc.date.available2020-03-26T17:40:25Z
dc.date.issued2009
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractBackground: Pituitary adenomas are common intracranial neoplasms, comprising 10 - 15% of all brain tumors. Data from autopsy studies suggest that pituitary adenomas develop in 17 - 25% of the population. Nevertheless, the pathogenesis of sporadic pituitary tumors still remains obscure. Objective: In this review, the roles of MAPK (mainly Ras/extracellular signal-regulated protein kinase (ERK)) and PI3K/Akt signaling pathways in pituitary tumorigenesis are summarised. Methods: A full data search was performed through PubMed over the years 2000 - 2009 with key words I pituitary, pituitary tumor, molecular biology, Akt, MAPK, PI3K, ERK', and all relevant publications have been included, together with selected publications prior to that date. Growth factor receptor mutations and overexpression, G protein mutations, other signaling pathway abnormalities or genetic syndromes associated with pituitary tumors are not discussed as these topics are behind the scope of this review. Conclusions: There are preclinical data and human pituitary tumor studies that are compatible with increased Ras/ERK and/or PI3K/Akt pathway activity in pituitary tumors. Future research focusing on scaffold proteins and signaling modulators regulating these pathways may help identify the initiating transforming events and accordingly new strategies may be developed targeting these pathways in pituitary tumors.en_US
dc.identifier.doi10.1517/14728220903170675en_US
dc.identifier.endpage1134en_US
dc.identifier.issn1472-8222en_US
dc.identifier.issn1744-7631en_US
dc.identifier.issue9en_US
dc.identifier.pmid19637976en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage1121en_US
dc.identifier.urihttps://dx.doi.org/10.1517/14728220903170675
dc.identifier.urihttps://hdl.handle.net/20.500.12395/23901
dc.identifier.volume13en_US
dc.identifier.wosWOS:000269597200008en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTAYLOR & FRANCIS LTDen_US
dc.relation.ispartofEXPERT OPINION ON THERAPEUTIC TARGETSen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectAkten_US
dc.subjectERKen_US
dc.subjectMAPKen_US
dc.subjectpathogenesisen_US
dc.subjectPI3Ken_US
dc.subjectpituitary tumoren_US
dc.titleTargeting MAPK (Ras/ERK) and PI3K/Akt pathways in pituitary tumorigenesisen_US
dc.typeReviewen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu